{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-26-001634","form_type":"8-K","ticker":"NXL","cik":"0001527352","company_name":"Nexalin Technology, Inc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.326318+00:00","generated_at":"2026-05-16T00:16:17.965374+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nexalin announces pivotal HALO Clarity trial for insomnia to support FDA de novo submission","bullets":["150-patient, triple-blinded, sham-controlled randomized study via decentralized NeuroCare virtual clinic with Lindus Health.","Designed to support planned FDA de novo submission for moderate to severe insomnia treatment.","Builds on prior published 120-patient study showing significant sleep improvements with no adverse effects.","Targets $multi-billion insomnia market; ~30M U.S. adults seek drug-free options."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-001634","json":"https://secwatch.observer/filing/0001829126-26-001634.json","markdown":"https://secwatch.observer/filing/0001829126-26-001634.md","text":"https://secwatch.observer/filing/0001829126-26-001634.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527352/000182912626001634/0001829126-26-001634-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527352/000182912626001634/nexalintec_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:16:17.965374+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}